Clevudine CAS NO.163252-36-6

clevudine is an antiviral drug for the treatment of hepatitis b. it is already approved for hbv in south korea and thephilippines. it is marketed by bukwang pharmaceuticals in south korea under the tradenames levovir and revovir.

under license from bukwang, pharmasset was developing the drug, but its phase iii clinical trial (international, multicenter, randomized, double-blind, 96 week quash studies) was terminated due to some myopathycases in patients. it's approval in south korea was revoked following these findings.